Latest Insider Transactions at Royalty Pharma PLC (RPRX)
This section provides a real-time view of insider transactions for Royalty Pharma PLC (RPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Royalty Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Royalty Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 04
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
60,000
-3.79%
|
$2,640,000
$44.78 P/Share
|
|
Jun 04
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
16,566
-50.0%
|
$745,470
$45.13 P/Share
|
|
Jun 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
62,500
-3.13%
|
$2,625,000
$42.11 P/Share
|
|
Jun 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-3.29%
|
$2,100,000
$42.13 P/Share
|
|
Jun 02
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
14,566
-30.54%
|
$597,206
$41.52 P/Share
|
|
May 21
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
100
-0.21%
|
$4,100
$41.0 P/Share
|
|
May 20
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
1,900
-3.82%
|
$77,900
$41.08 P/Share
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Indirect |
2,355,190
+50.0%
|
-
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
679,760
+50.0%
|
-
|
|
May 07
2021
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
1,875,860
+47.74%
|
-
|
|
May 07
2021
|
Terrance P. Coyne EVP & CFO |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+50.0%
|
-
|
|
May 07
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
1,320,800
+46.48%
|
-
|
|
May 07
2021
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Direct |
49,700
+50.0%
|
-
|
|
May 07
2021
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
2,325,000
+50.0%
|
-
|
|
Apr 14
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
55,714
-21.79%
|
$2,339,988
$42.1 P/Share
|
|
Apr 14
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
69,822
-21.81%
|
$2,932,524
$42.13 P/Share
|
|
Apr 12
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
359
-0.14%
|
$15,078
$42.32 P/Share
|
|
Apr 12
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
449
-0.14%
|
$18,858
$42.32 P/Share
|
|
Mar 31
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+7.89%
|
$36,720
$45.9 P/Share
|
|
Mar 31
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+5.1%
|
$36,720
$45.9 P/Share
|
|
Mar 22
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
54,729
-9.75%
|
$2,517,534
$46.57 P/Share
|
|
Mar 22
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
43,927
-14.64%
|
$2,020,642
$46.32 P/Share
|
|
Mar 03
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-9.3%
|
$4,500,000
$45.37 P/Share
|
|
Mar 02
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-12.7%
|
$4,700,000
$47.39 P/Share
|
|
Mar 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-12.64%
|
$4,700,000
$47.37 P/Share
|
|
Mar 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
125,000
-12.76%
|
$5,875,000
$47.37 P/Share
|
|
Feb 25
2021
|
Henry A Fernandez Director |
BUY
Open market or private purchase
|
Indirect |
25,700
+50.0%
|
$1,182,200
$46.83 P/Share
|
|
Dec 31
2020
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
500,000
+50.0%
|
-
|
|
Dec 31
2020
|
James F. Reddoch EVP & Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
400,000
+37.26%
|
-
|
|
Dec 31
2020
|
Terrance P. Coyne EVP & CFO |
BUY
Conversion of derivative security
|
Indirect |
400,000
+46.44%
|
-
|
|
Dec 31
2020
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+5.4%
|
$36,900
$45.69 P/Share
|
|
Dec 31
2020
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
820
+8.6%
|
$36,900
$45.69 P/Share
|
|
Dec 18
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101,050
-0.26%
|
$4,446,200
$44.02 P/Share
|
|
Dec 17
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,200,000
-15.65%
|
$309,600,000
$43.92 P/Share
|
|
Dec 16
2020
|
William E Ford Director |
SELL
Other acquisition or disposition
|
Indirect |
42,101
-7.24%
|
-
|
|
Oct 20
2020
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
428,420
+31.72%
|
-
|
|
Oct 20
2020
|
William E Ford Director |
BUY
Conversion of derivative security
|
Indirect |
581,870
+50.0%
|
-
|
|
Oct 20
2020
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
463,200
-100.0%
|
$19,454,400
$42.0 P/Share
|
|
Oct 20
2020
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
463,200
+50.0%
|
-
|
|
Sep 30
2020
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+6.29%
|
$37,310
$41.17 P/Share
|
|
Sep 30
2020
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
910
+6.35%
|
$37,310
$41.17 P/Share
|
|
Sep 30
2020
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
613
+7.21%
|
$25,133
$41.17 P/Share
|
|
Jun 18
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000,000
+6.12%
|
$84,000,000
$28.0 P/Share
|
|
Jun 18
2020
|
Adage Capital Partners Gp, L.L.C. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
43,015,330
+50.0%
|
-
|
|
Jun 18
2020
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
241,810
+50.0%
|
-
|
|
Jun 18
2020
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$560,000
$28.0 P/Share
|
|
Jun 16
2020
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
493,750
+50.0%
|
-
|
|
Dec 12
2002
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
40,010
-29.26%
|
$1,640,410
$41.98 P/Share
|